Roche’s dual-stain test received FDA approval and a CE mark for the identification of people at high risk of developing HPV-positive cervical precancer and cancer. Credit: NTshutterth / Shutterstock.

The World Health Organization (WHO) has updated its cervical cancer prevention guidelines to include dual-stain cytology testing with Roche’s CINtec PLUS Cytology test.

CINtec PLUS Cytology previously received FDA approval and a CE mark for the identification of people at high risk of developing cervical precancer and cancer among those who are human papillomavirus (HPV)-positive.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The dual-stain test’s positive result indicates an increased pre-cancer or cancer risk, prompting immediate colposcopy, while a negative result suggests a low risk, allowing for retesting at a later date.

This test detects the presence of two biomarkers, p16 and Ki-67, within the same cell, indicating a potential transformation into a cancerous state.

It offers crucial information for laboratories, clinicians, and patients to make informed decisions about patient management, potentially reducing the need for follow-up visits and associated costs.

See Also:

It can be performed using the same liquid sample collected for HPV or Pap cytology tests, avoiding the need for additional samples.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The endorsement by WHO follows a similar update by the American Society for Colposcopy and Cervical Pathology (ASCCP) in March, which also included dual-stain cytology as a triage test for HPV-positive individuals.

Roche previously received WHO prequalification for its cobas HPV test on the cobas 4800 system, complementing its portfolio of HPV tests on the 4800, 5800, 6800, and 8800 systems, which are now approved for both clinician-collected and self-collected samples.

Roche Diagnostics CEO Matt Sause said: “Adding dual-stain cytology to the WHO guidelines further reinforces the value of our biomarker-based CINtec PLUS Cytology test to identify patients with an elevated risk of cervical cancer.

“HPV infections can cause cervical cancer, a potentially deadly disease that is highly preventable. Consequently, it is critical to determine who is most at risk.”

In July this year, Roche completed the acquisition of LumiraDx‘s Point of Care technology for up to $350m.